Inactive Instrument

ENTREMED Stock Nasdaq

Pharmaceuticals

End-of-day quote Nasdaq Other stock markets
- ^USD	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	3.5M 3.01M 2.77M 2.61M 4.89M 331M 4.94M 32.79M 12.77M 162M 13.12M 12.84M 561M	P/E 2026 *	-0.12x	P/E 2027 *	-0.12x
Enterprise Value	3.5M 3.01M 2.77M 2.61M 4.89M 331M 4.94M 32.79M 12.77M 162M 13.12M 12.84M 561M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	53.62%	Yield 2026 *	-	Yield 2027 *	-

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.61%	-1.94%	+39.00%	+150.72%	1,001B
JOHNSON & JOHNSON	-0.20%	-0.77%	+51.51%	+43.20%	566B
ABBVIE INC.	+0.40%	-1.31%	+16.56%	+60.47%	393B
ROCHE HOLDING AG	+0.35%	+2.29%	+24.04%	+16.53%	326B
NOVARTIS AG	+0.54%	+1.24%	+26.11%	+32.66%	276B
ASTRAZENECA PLC	+0.62%	-0.68%	+25.42%	+14.82%	277B
NOVO NORDISK A/S	+3.67%	+2.68%	-40.43%	-46.31%	193B
AMGEN INC.	-0.77%	+0.95%	+17.69%	+51.46%	188B
GILEAD SCIENCES, INC.	+2.36%	+1.38%	+14.80%	+61.34%	158B
Average	+0.82%	+0.35%	+19.41%	+42.76%	375.2B
Weighted average by Cap.	+0.48%	-0.41%	+28.03%	+67.52%

	2026 *	2027 *
Net sales	-	-
Net income	-24.73M -21.31M -19.62M -18.42M -34.59M -2.34B -34.96M -232M -90.33M -1.14B -92.79M -90.82M -3.97B	-26.51M -22.85M -21.04M -19.75M -37.09M -2.51B -37.48M -249M -96.85M -1.23B -99.49M -97.38M -4.25B
Net Debt	-	-

ENTREMED Stock Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news : ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile